Bill Smith

发表

Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection

Xuping Xie, P. Shi, R. Mackman, 2022, Antiviral Research.

E. Reyner, M. Ullah, M. West, 2013 .

Single‐Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers

A. Burstein, M. Gibbs, H. Faessel, 2006, Journal of clinical pharmacology.

Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection

William A. Lee, A. Gigliotti, R. Mackman, 2021, Science Translational Medicine.

Expression and Functional Analysis of Hepatic Cytochromes P450, Nuclear Receptors, and Membrane Transporters in 10- and 25-Week-Old db/db Mice

Tao Zhang, E. Y. Zhang, Ying Jiang, 2010, Drug Metabolism and Disposition.

Characterization of Seasonal Pharmacokinetic Variability in Woodchucks

S. Balsitis, R. Subramanian, Jim Zheng, 2020, Drug Metabolism and Disposition.

Expression and Functional Analysis of Hepatic Cytochromes P450, Nuclear Receptors, and Membrane Transporters in 10- and 25-Week-Old db/db Mice

Tao Zhang, E. Y. Zhang, Ying Jiang, 2010, Drug Metabolism and Disposition.

Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development.

Xingrong Liu, Cuiping Chen, Bill Smith, 2003, Current drug metabolism.

Pharmacokinetics, Metabolism, and Excretion of [14C]Axitinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Humans

D. Dalvie, Y. Pithavala, B. Hee, 2014, Drug Metabolism and Disposition.

Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development

M. Warr, R. Subramanian, Y. Xin, 2018, Drug Metabolism and Disposition.

Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration

J. Cianfrogna, F. Nelson, Xingrong Liu, 2006, Drug Metabolism and Disposition.

Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse Models

Paolo Vicini, Shinji Yamazaki, Bill J Smith, 2012, Journal of Pharmacology and Experimental Therapeutics.

Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells

Xuping Xie, P. Shi, J. Bilello, 2021, Antimicrobial agents and chemotherapy.

Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human.

S. D. de Morais, E. Tate, W. Dower, 2009, Pharmacological research.

THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

Xi Chen, Karthik Venkatakrishnan, Matthew Troutman, 2005, Drug Metabolism and Disposition.

Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

Bill J Smith, T. Maurer, K. Beaumont, 2009, Journal of clinical pharmacology.

In Vitro Characterization of Axitinib Interactions with Human Efflux and Hepatic Uptake Transporters: Implications for Disposition and Drug Interactions

Caroline A. Lee, E. Reyner, M. Ullah, 2013, Drug Metabolism and Disposition.

Microsoft Word-39120393-file00.docx

Caroline A. Lee, E. Reyner, M. Ullah, 2013 .

Development of a computational approach to predict blood-brain barrier permeability.

Meihua Tu, Bill J Smith, Xingrong Liu, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects

G. S. Walker, T. R. Johnson, J. Christensen, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

In Vitro Kinetic Characterization of Axitinib Metabolism

G. S. Walker, J. Bauman, T. Goosen, 2016, Drug Metabolism and Disposition.

DMD065615 102..114

G. S. Walker, J. Bauman, T. Goosen, 2015 .

Comparison of Tissue Abundance of Non-Cytochrome P450 Drug-Metabolizing Enzymes by Quantitative Proteomics between Humans and Laboratory Animal Species

S. Heyward, B. Prasad, P. Fan, 2021, Drug Metabolism and Disposition.

18O-Enabled High-Throughput Acyl Glucuronide Stability Assay.

Xingrong Liu, Qin Yue, Jennifer Tang, 2022, Chemical research in toxicology.

Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding

Ernesto Callegari, Bill J Smith, J. Cianfrogna, 2005, Journal of Pharmacology and Experimental Therapeutics.

Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection

Y. Lai, Jianhong Wang, Heather Zhang, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

Transporter Gene Regulation in Sandwich Cultured Human Hepatocytes Through the Activation of Constitutive Androstane Receptor (CAR) or Aryl Hydrocarbon Receptor (AhR)

Y. Lai, C. Niu, Bill Smith, 2021, Frontiers in Pharmacology.

CHARACTERIZATION OF DIFFERENTIAL TISSUE ABUNDANCE OF MAJOR NON-CYP ENZYMES IN HUMAN.

S. Heyward, A. Basit, E. Kelly, 2020, Molecular pharmaceutics.

Regional Proteomic Quantification of Clinically Relevant Non-Cytochrome P450 Enzymes along the Human Small Intestine

A. Basit, Albert P. Li, K. Thummel, 2020, Drug Metabolism and Disposition.

Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo

R. Subramanian, Y. Lai, E. Murakami, 2019, Drug Metabolism and Disposition.

Application of Target-Mediated Drug Disposition Model to Small Molecule Heat Shock Protein 90 Inhibitors

S. Yamazaki, P. Vicini, Ying Jiang, 2013, Drug Metabolism and Disposition.

Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model

T. R. Johnson, S. Yamazaki, Bill Smith, 2015, Drug Metabolism and Disposition.

An industrial perspective on contemporary applications of PBPK models in drug discovery and development.

Bill Smith, 2012, Biopharmaceutics & drug disposition.

Progress in Brain Penetration Evaluation in Drug Discovery and Development

Bill J Smith, Xingrong Liu, Cuiping Chen, 2008, Journal of Pharmacology and Experimental Therapeutics.

Human pharmacokinetics prediction with an in vitro–in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection

Jia Hao, Jianhong Wang, S. Lazerwith, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

In Vitro Hepatic Uptake in Human and Monkey Hepatocytes in the Presence and Absence of Serum Protein and Its In Vitro to In Vivo Extrapolation

Y. Lai, Yeojin Park, C. Niu, 2020, Drug Metabolism and Disposition.

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models

Shinji Yamazaki, Bill J Smith, J. Christensen, 2008, Drug Metabolism and Disposition.

Comparison of the disposition and in vitro metabolism of 4-vinylcyclohexene in the female mouse and rat.

D. E. Carter, I. Sipes, B. J. Smith, 1990, Toxicology and applied pharmacology.